Latest news with #PACIFIC
Sydney Morning Herald
12-05-2025
- Science
- Sydney Morning Herald
This project could put aviation conspiracy nuts out of business
Chemtrail spotters rattled by the sight of clouds streaking the sky, sit tight: researchers in Europe are working on eliminating contrails, the high-altitude condensation trails on which the conspiracy theory rests. A European Union-backed project called PACIFIC is focused on understanding climate-neutral aviation with the goal of minimising non-CO2 emissions from planes. Non-CO2 emissions are made up of water vapour, nitrogen oxides, carbon monoxide and soot, which together create the streaks of clouds in the sky. These streaks have spawned the well-established chemtrail conspiracy, which is the mistaken belief that contrails are actually chemical or biological agents being sprayed on the public for nefarious purposes. And contrails are a problem when it comes to our world getting hotter. Just 10 per cent of flights create 80 per cent of planet-warming contrails. They most commonly occur on long-haul flights, which are essential to almost all Australian international travel. Under certain conditions, contrails form when water vapour, non-CO2 emissions and soot emitted from engines freeze to form streaks of ice crystal clouds. The streaks run for an average length of 150 kilometres, or about 10 minutes of flying. Most – but not all – contrails warm the atmosphere. Loading While only 10 to 15 per cent of contrails are persistent, and most of these last only a few hours, 'they can exacerbate climate change by trapping heat radiating from the Earth's surface', says Airbus. Understanding more about the specific conditions that create warming contrails is part of the mission of the Particle emissions, Air quality and Climate Impact related to Fuel Composition and Engine Cycle (PACIFIC) consortium. It's a gathering of 11 European partners organised to advance climate neutral aviation to cut non-CO2 emissions.
The Age
12-05-2025
- Science
- The Age
This project could put aviation conspiracy nuts out of business
Chemtrail spotters rattled by the sight of clouds streaking the sky, sit tight: researchers in Europe are working on eliminating contrails, the high-altitude condensation trails on which the conspiracy theory rests. A European Union-backed project called PACIFIC is focused on understanding climate-neutral aviation with the goal of minimising non-CO2 emissions from planes. Non-CO2 emissions are made up of water vapour, nitrogen oxides, carbon monoxide and soot, which together create the streaks of clouds in the sky. These streaks have spawned the well-established chemtrail conspiracy, which is the mistaken belief that contrails are actually chemical or biological agents being sprayed on the public for nefarious purposes. And contrails are a problem when it comes to our world getting hotter. Just 10 per cent of flights create 80 per cent of planet-warming contrails. They most commonly occur on long-haul flights, which are essential to almost all Australian international travel. Under certain conditions, contrails form when water vapour, non-CO2 emissions and soot emitted from engines freeze to form streaks of ice crystal clouds. The streaks run for an average length of 150 kilometres, or about 10 minutes of flying. Most – but not all – contrails warm the atmosphere. Loading While only 10 to 15 per cent of contrails are persistent, and most of these last only a few hours, 'they can exacerbate climate change by trapping heat radiating from the Earth's surface', says Airbus. Understanding more about the specific conditions that create warming contrails is part of the mission of the Particle emissions, Air quality and Climate Impact related to Fuel Composition and Engine Cycle (PACIFIC) consortium. It's a gathering of 11 European partners organised to advance climate neutral aviation to cut non-CO2 emissions.
Yahoo
04-04-2025
- Health
- Yahoo
Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting
VALBY, Denmark, April 4, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) will present positive interim results from the open-label extension of the PACIFIC trial investigating bexicaserin, in addition to new analyses from clinical trials and real-world data with eptinezumab. H. Lundbeck A/S (Lundbeck) today announced that recent pipeline data will be presented at the 2025 AAN Annual Meeting in San Diego, U.S. The data includes an oral presentation of the six-month results from the open-label extension (OLE) of the Phase 1b/2a PACIFIC trial of bexicaserin, a novel treatment under development for seizures associated with Developmental and Epileptic Encephalopathies (DEEs).1 DEEs are the most severe group of epilepsies characterized by drug-resistant seizures, and developmental slowing or regression.2 "DEEs can be caused by a range of acquired, syndromal, and genetic etiologies, with more than 900 genes implicated. However, only a few subtypes currently have approved therapies, leaving many patients in need. The DEE-inclusive PACIFIC trial and six-month OLE data indicate that bexicaserin may be able to help address this unmet need across multiple DEE types, and highlights Lundbeck's expanding commitment to the neuro-rare space. We look forward to engaging with the global neuroscience community at AAN to discuss the data and potential of bexicaserin to support patients, caregivers and healthcare professionals in the management of DEEs," said Johan Luthman, EVP and Head of Research & Development at Lundbeck. The OLE included patients who successfully completed the PACIFIC trial3 and was designed to evaluate the long-term safety (up to 52 weeks), tolerability, and efficacy of bexicaserin in a cohort of participants with DEEs who were newly exposed to bexicaserin for at least 6 months.1 The OLE interim analysis showed that bexicaserin continues to exhibit a favourable safety and tolerability profile at six months, consistent with the safety profile observed during the PACIFIC trial. All bexicaserin treatment-naive patients (n=9) successfully transitioned from placebo to bexicaserin, reinforcing the tolerability of bexicaserin in an inclusive DEE population. In this placebo-bexicaserin switch population, a 57.3% reduction in countable motor seizures and 61.2% reduction in total seizures was observed, consistent with the response in non-naive participants at 6 months (n=32).* Moreover, more than half of patients newly exposed to bexicaserin (n=5/9) experienced a ≥50% reduction from baseline in countable motor seizures.1* In addition, Lundbeck will present recent post-hoc analyses and real-world data for eptinezumab investigating meaningful endpoints, such as good days per month†, and sustained treatment response. Lundbeck remains focused on raising the bar around preventive treatment expectations in migraine and increasing the understanding of the holistic impact of migraine on quality of life. *As compared to baseline at entry into PACIFIC study. †As reported by trial patients based on individual migraine experience Details of Lundbeck presentations at AAN 2025: Bexicaserin Oral Presentation Monday, April 7, Session S20, 4:18 – 4:30pm PT Title: Safety, Tolerability, and Efficacy of Bexicaserin in a Cohort of Participants with Developmental and Epileptic Encephalopathies: Interim Results of a Phase 1b/2a PACIFIC Study Open-Label Extension Eptinezumab Poster Presentations: Title: Long-term Maintenance of ≥50% and ≥75% Migraine Response With Eptinezumab in Patients With High-frequency Episodic Migraine and Chronic Migraine and 2-4 Prior Migraine Preventive Treatment Failures4 I Poster number: P12.005 Title: Patient-reported Impact of ≥75% Increase in Good Days/Month on Migraine Symptoms, Quality of Life, and Brain Fog: Real-world Study of Adults With Chronic Migraine Treated With Eptinezumab5 I Poster number: P12.010 Title: Long-term Reductions in Monthly Headache Days With Eptinezumab Treatment in Adults With Chronic Migraine: Results From the PREVAIL Study6 I Poster number: P12.003 About Bexicaserin Bexicaserin (LP352) is an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist with no observed impact on 5-HT2B and 5-HT2A receptor subtypes. It is being evaluated in a global Phase III clinical program (the DEEp Program). The FDA has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age and older. Bexicaserin is an investigational compound that is not approved for marketing by any regulatory authority worldwide. The PACIFIC trial was a randomised, double-blind, placebo-controlled, DEE-inclusive trial (NCT05364021) in 52 participants with Dravet syndrome, Lennox-Gastaut syndrome, or DEE Other, who had ≥4 countable motor seizures during the 28-day baseline period, and who were on a stable regimen of 1 to 4 concomitant antiseizure medications.3 About eptinezumab (Vyepti®) Eptinezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) which was purposefully developed for IV administration. The efficacy and safety of eptinezumab 100 mg and 300 mg was investigated in two phase III clinical trials (PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine), where eptinezumab met its primary endpoint of decrease in mean monthly migraine days (MMD) over weeks 1-12 in both episodic and chronic migraine. Furthermore, the clinical trial program observed a treatment benefit over placebo that was observed for both doses of eptinezumab as early as day 1 post-infusion. The safety of eptinezumab was evaluated in more than 2,000 adult patients with migraine who received at least one dose of eptinezumab. The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity. Approximately 8% of patients on 300 mg, 6% of patients on 100 mg and 6% of patients on placebo in PROMISE-1 and PROMISE-2 experienced nasopharyngitis. In PROMISE-1 and PROMISE-2, 1.9% of patients treated with eptinezumab discontinued treatment due to adverse reactions. Eptinezumab was approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults in February 2020, and in January 2022, eptinezumab was granted marketing authorization by the European Medicines Agency (EMA) for the prophylaxis of migraine in adults who have at least four migraine days per month. Today, eptinezumab is launched in the U.S. market, as well as in more than 30 markets worldwide. Contacts Marie Petterson Jens Høyer Media Relations Lead, Corp. Communication Vice President, Head of Investor Relations MEEP@ JSHR@ +45 29 82 21 82 +45 30 83 45 01Palle Holm OlesenVice President, Investor RelationsPALO@ 30 83 24 26 About H. Lundbeck A/S Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases. Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments. As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology. We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole. Lundbeck has approximately 5,500 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site and connect with us via LinkedIn. References: 1. American Academy of Neurology Annual Meeting 2025. Safety, Tolerability, and Efficacy of Bexicaserin in a Cohort of Participants with Developmental and Epileptic Encephalopathies: Interim Results of a Phase 1b/2a PACIFIC Study Open-Label Extension. 2. Sheffer I, et al. Epilepsia. 2025 Feb 10.1111/epi.18265. 3. Kaye R, et al. Efficacy and safety of bexicaserin (LP352) in adolescent and adult participants with developmental and epileptic encephalopathies: Results of the phase 1b/2a PACIFIC study. Presented at the Annual Meeting of the American Academy of Neurology; April 13-18, 2024 4. Ailani J, et al. Poster Presentation. American Academy of Neurology Annual Meeting 2025. 5. Argoff C, et al. Poster presentation. American Academy of Neurology Annual Meeting 2025. 6. Starling A, et al. Poster Presentation. American Academy of Neurology Annual Meeting 2025. CONTACT: H. Lundbeck A/SOttiliavej 9, 2500 Valby, Denmark+45 3630 1311info@ This information was brought to you by Cision The following files are available for download: Lundbeck AAN_ Final View original content: SOURCE H. Lundbeck A/S Sign in to access your portfolio
Broadcast Pro
14-03-2025
- Business
- Broadcast Pro
Cobalt Digital to unveil lineup of IPMX-compliant solutions at NAB 2025
Cobalt has announced plans to showcase a plug-and-play ST 2110 experience at NAB with an expanded lineup of IPMX-compliant products, along with new tools for its IP multiviewer and ARIA audio monitors. Cobalt Digital has announced plans to unveil an expanded lineup of IPMX-compliant solutions at NAB Show 2025. The company will showcase enhanced versions of its SAPPHIRE mini converters and PACIFIC encoders, now equipped with IPMX support and additional functionalities. Visitors to NAB booth will also get a first look at the upgraded UltraBlue IP-MV multiviewer with new tools, as well as the latest addition to the ARIA series, the ARIA Audio Monitors. These innovations bolster Cobalt's extensive portfolio, which includes support for ST 2110 technology. The SAPPHIRE BBG mini converters deliver compact, high-performance solutions for seamless content display on HDMI monitors. Supporting single, dual and quad-channel configurations, these converters offer dual SFP cages with 10G and 25G Ethernet compatibility, audio sample rate conversion and the ability to mix audio channels independently from video synchronisation. Their space-saving design and silent operation make them ideal for control rooms and editing suites. Cobalt's PACIFIC 9992-ENC encoder, a highly flexible MPEG-2/AVC/HEVC solution, now supports ST 2110-20 (baseband) and optional ST 2110-22 for JPEG-XS video. With the capability to encode up to four 1080p60 signals or a single 4K feed, PACIFIC provides seamless integration into IPMX workflows, allowing users to mix SDI, ST 2110, and IPMX sources within the same device. Additional features include support for ST 2110-30 audio with up to 16 channels per essence, ST 2110-40 ancillary data and dual SFP cages for ST 2022-7 seamless switching. The newly introduced COBALT ARIA AUD-MON Audio Monitor supports multiple input types, including SDI (up to 12G), MADI, AES, analog, and GPI automation. Featuring a touch display for configuration, live video thumbnail previews, and SDI output monitoring, this 1RU, 4-pound device offers PoE++ support and redundant external power options. Cobalt will also highlight the ARIA OG-AUD4-DANTE, a bi-directional audio embedder/de-embedder router card featuring 12G-SDI, MADI, AES, and DANTE connectivity. The UltraBlue IP-MV Multiviewer, a flexible software-based solution for IP-based audio and video monitoring, is receiving significant updates, including enhanced support for compressed and baseband streams. With its web-based interface, customisable mosaic layouts, graphic overlays, tally indicators, and UMDs, the UltraBlue IP-MV offers a scalable solution tailored to evolving broadcast needs. It supports multiple HDMI display configurations and incorporates closed-captioning and fully configurable audio routing. Stand SL 5123
